<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05104697</url>
  </required_header>
  <id_info>
    <org_study_id>1697181</org_study_id>
    <nct_id>NCT05104697</nct_id>
  </id_info>
  <brief_title>TMS for Improving Response Inhibition in Adolescents With OCD</brief_title>
  <official_title>TMS for Improving Response Inhibition in Adolescents With OCD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bradley Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Butler Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Minnesota</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Bradley Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will examine whether inhibition of the pre-supplementary motor area (pSMA) using&#xD;
      transcranial magnetic stimulation (TMS) normalizes activity in pSMA-connected circuits,&#xD;
      improves response inhibition, and reduces compulsions in adolescents with OCD.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 2022</start_date>
  <completion_date type="Anticipated">September 2023</completion_date>
  <primary_completion_date type="Anticipated">July 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>We will use a within-subject, counterbalanced design comparing TMS vs Sham in a brief 2-visit protocol</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in response time on stop trials of the stop signal task</measure>
    <time_frame>Change from pre (within 1 hour before) to post (within 1 hour after) intervention</time_frame>
    <description>Computerized task</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in frontocentral P3 amplitude on Electroencephalogram (EEG)</measure>
    <time_frame>Change from pre (within 1 hour before) to post (within 1 hour after) intervention</time_frame>
    <description>Electroencephalogram (EEG)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>3-item self-report symptom questionnaire</measure>
    <time_frame>post (within 1 hour after) intervention</time_frame>
    <description>self-rated mood and OCD symptoms</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Obsessive-Compulsive Disorder</condition>
  <arm_group>
    <arm_group_label>TMS at visit 1, Sham at visit 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>At visit 1, participants will receive active TMS using continuous theta burst over the preSMA. At Visit 2, participants will receive sham (fake) TMS in the same location.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham at visit 1, TMS at visit 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>At visit 2, participants will receive active TMS using continuous theta burst over the preSMA. At Visit 1, participants will receive sham (fake) TMS in the same location.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Transcranial Magnetic Stimulation</intervention_name>
    <description>Teens will receive TMS at either visit 1 or visit 2</description>
    <arm_group_label>Sham at visit 1, TMS at visit 2</arm_group_label>
    <arm_group_label>TMS at visit 1, Sham at visit 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 13-18 years&#xD;
&#xD;
          -  Presence of OCD, as indicated by score on the Children's Yale-Brown&#xD;
             Obsessive-Compulsive Scale&#xD;
&#xD;
          -  Patient and one parent speak English fluently (to ensure comprehension of study&#xD;
             measures and instructions&#xD;
&#xD;
          -  Right-handed&#xD;
&#xD;
          -  If taking psychotropic medications, these have been stable for &gt; 6 weeks and are&#xD;
             expected to remain stable for the approximately 3-week study protocol&#xD;
&#xD;
          -  If currently in psychotherapy, symptom improvement has plateaued (no improvement in&#xD;
             the past 6 weeks and symptoms expected to remain stable for the approximately 3-week&#xD;
             study protocol)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  â€¢ Medical conditions contraindicated for TMS or EEG, including history of intracranial&#xD;
             pathology, increased intracranial pressure, epilepsy or seizures, traumatic brain&#xD;
             injury, brain tumor, stroke, implanted medical devices, possible pregnancy (female of&#xD;
             childbearing age not using effective contraception), or any other serious medical&#xD;
             condition (note that medical history will be reviewed by a study physician prior to&#xD;
             TMS administration)&#xD;
&#xD;
               -  Metal in the head, except mouth (e.g., cochlear implant, implanted brain&#xD;
                  stimulators, aneurysm clips)&#xD;
&#xD;
               -  Active suicidality or psychosis&#xD;
&#xD;
               -  Existing diagnosis of Bipolar disorder, Autism Spectrum Disorder, mental&#xD;
                  retardation, or cognitive disability&#xD;
&#xD;
               -  Substance abuse or dependence&#xD;
&#xD;
               -  Taking a stimulant medication (and unwilling to forgo on study visit days)&#xD;
&#xD;
               -  Taking medication with the potential to lower seizure threshold (e.g.,&#xD;
                  neuroleptics, antipsychotics)&#xD;
&#xD;
               -  Patient is a ward of the state&#xD;
&#xD;
               -  Family history of epilepsy&#xD;
&#xD;
               -  History of syncope&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Kristen Benito, PhD</last_name>
    <phone>401-432-1468</phone>
    <email>kbenito@lifespan.org</email>
  </overall_contact>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 9, 2021</study_first_submitted>
  <study_first_submitted_qc>October 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 3, 2021</study_first_posted>
  <last_update_submitted>October 21, 2021</last_update_submitted>
  <last_update_submitted_qc>October 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Bradley Hospital</investigator_affiliation>
    <investigator_full_name>Kristen Benito</investigator_full_name>
    <investigator_title>Associate Professor (Research)</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Compulsive Personality Disorder</mesh_term>
    <mesh_term>Obsessive-Compulsive Disorder</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>August 12, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/97/NCT05104697/ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

